Study Title: A Phase 1/2, First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of DF9001 as a Monotherapy and in Combination with Nivolumab in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Albert Lockhart, at lockhara@musc.edu.Study Coordinator, Bria Sanders, at sandebri@musc.edu.Trial opened at the following institutions: Medical University of South Carolina